Pharmsynthez to invest $55 million in large-scale production of heart disease drugs in Russia

8 June 2021

Pharmsynthez, one of Russia’s leading drugmakers, will invest about 4 billion roubles ($55 million) to establish large-scale production of heart disease drugs in the Tyumen region of Russia, according to recent statements by the company and some local media reports.

An agreement between the company and the Tyumen governor Alexander Moor was signed during the St Petersburg International Economic Forum and involves the launch of production of up to 30 various drugs for the treatment of heart diseases.

According to Mr Moor, the capacity of the new enterprise will be sufficient to cover 20% about of Russia's needs for such drugs. The new project will create more than 200 new jobs, while its other details are not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK